September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Varun Bafna: The Power of Extended Half-Life Factor IX in Enabling Safe Major Surgeries

Varun Bafna/LinkedIn

Mar 20, 2026, 15:42

Varun Bafna: The Power of Extended Half-Life Factor IX in Enabling Safe Major Surgeries

Varun Bafna, Hematologist, Hemato-Oncologist and BMT Physician at Dr. Bafna Star Superspeciality Clinics, shared on LinkedIn:

”A rare and rewarding clinical experience in hemophilia care.

We recently managed an 81-year-old gentleman with severe Hemophilia B (FIX <1%, inhibitor negative) — possibly among the oldest patients to successfully undergo major orthopedic surgery in this setting.

Indication: Left gleno-humeral joint osteoarthritis secondary to recurrent hemarthrosis
Procedures: Left shoulder joint replacement plus prostate surgery

With meticulous perioperative planning, we administered a single pre-operative dose of Refixia (80 IU/kg; 4000 IU) 1–2 hours prior to incision.

Surgery was completed successfully
No intraoperative or postoperative bleeding complications
No additional factor dosing required
Post-operative course remained stable
Inhibitor screening remained negative

This case highlights the power of extended half-life Factor IX in enabling safe major surgeries with reduced dosing burden — even in elderly hemophilia patients with advanced joint disease.

A special acknowledgment to the surgical team:

Dr. Namdev Gorgille, Shoulder Specialist, Miraj
Dr. Naaz Namaje, Anaesthetist

Looking ahead: With emerging therapies like Concizumab, there is growing evidence supporting prophylaxis in hemophilia (including inhibitor and non-inhibitor patients) to reduce bleeding episodes and prevent long-term joint damage.

Such approaches may further improve surgical readiness and outcomes in the future.

A step forward in advancing comprehensive hemophilia care.”

Varun Bafna: The Power of Extended Half-Life Factor IX in Enabling Safe Major Surgeries